Volume 14, Number 1—January 2008
THEME ISSUE
International Polar Year
Research
International Circumpolar Surveillance System for Invasive Pneumococcal Disease, 1999–2005
, Shelley L. Deeks†1, Tammy Zulz*, Dana Bruden*, Christine Navarro†, Marguerite Lovgren‡, Louise Jette§, Karl G. Kristinsson¶, Gudrun Sigmundsdottir¶, Knud Brinkløv Jensen#, Oistein Lovoll**, J. Pekka Nuorti††, Elja Herva‡‡, Anders Nystedt§§, Anders Sjostedt¶¶, Anders Koch##, Thomas W. Hennessy*, Alan J. Parkinson*, and the International Circumpolar Surveillance System for Invasive Pneumococcal Disease Working Group
Table 7
Clinical findings for invasive pneumococcal disease
| Findings | Alaska, 1999–2005, no. (%) | Northern Canada, 1999–2005, no. (%) | Greenland, 2000–2005, no. (%) | Norway, 2000–2005, no. (%) |
|---|---|---|---|---|
| Pneumonia with bacteremia | 466 (61) | 162 (65) | 36 (52) | 2,598 (45) |
| Sepsis | 154 (20) | 41 (16) | 14 (20) | 1,404 (25) |
| Bacteremia | 20 (3) | 13 (5) | 0 | 864 (15) |
| Meningitis with bacteremia | 53 (7) | 16 (6) | 14 (20) | 454 (8) |
| Other* | 76 (10) | 19 (8) | 5 (7) | 405 (7) |
| Total | 769 (100) | 251 (100) | 69 (100) | 5,725 (100) |
*Empyema, cellulitis, necrotizing fasciitis, septic arthritis.
1Current affiliation: National Centre for Immunisation, Research and Surveillance, Westmead, New South Wales, Australia
2The International Circumpolar Surveillance System for Invasive Pneumococcal Disease Working Group: Jean-François Proulx (Department of Public Health, Nunavik Regional Board of Health and Social Services, Quebec City, Quebec, Canada); Robert Carlin (Department of Public Health, Cree Board of Health and Social Services of James Bay, Montreal, Quebec, Canada); Andre Corriveau, Cheryl Case (Northwest Territory Department of Health and Social Services, Yellowknife, Northwest Territories, Canada); Bryce Larke, Colleen Hemsley (Yukon Health and Social Services, Whitehorse, Yukon, Canada); Isaac Sobel, Carolina Palacios (Nunavut Department of Health, Iqaluit, Nunavut, Canada); Gregory Tyrell, Marguerite Lovgren (National Centre for Streptococcus, Edmonton, Alberta, Canada); Alisa Reasonover, Michael G. Bruce, Tammy Zulz, Dana Bruden, Thomas W. Hennessy, Alan J. Parkinson (Centers for Disease Control and Prevention, Anchorage, Alaska, USA); Shelley L. Deeks (National Centre for Immunisation, Research and Surveillance, Westmead, New South Wales, Australia); Christine Navarro (Public Health Agency of Canada, Ottawa, Ontario, Canada); Louise Jette (Quebec Public Health Laboratory, Ste. Anne-de-Bellevue, Quebec, Canada); Karl Kristinsson, Gudrun Sigmundsdottir (Landspitali University Hospital, Reykjavik, Iceland); Knud Brinkløv Jensen (Institution of the Chief Medical Officer, Nuuk, Greenland); Oistein Lovoll (Norwegian Institute of Public Health, Oslo, Norway); J. Pekka Nuorti (National Public Health Institute, Helsinki, Finland); Elja Herva (National Public Health Institute, Oulu, Finland); Anders Sjostedt (Umea University, Umea, Sweden); Anders Nystedt (Sunderby Hospital, Lulea, Sweden); and Anders Koch (Statens Serum Institut, Copenhagen, Denmark)